MechtlerTPStarySMetzTFet al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379:335-341.
2.
MeiklePJHopwoodJJClagueAECareyWF.Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
3.
BeutlerE.Discrepancies between genotype and phenotype in hematology: an important frontier. Blood. 2001;98:2597-2602.
4.
GrabowskiGA.Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263-1271.
5.
MistryPKBelmatougNvom DahlSGiuglianiR.Understanding the natural history of Gaucher disease. Am J Hematol. 2015;90(suppl 1):S6-S11.
6.
WeissKGonzalezANLopezGPedoeimLGrodenCSidranskyE.The clinical management of type 2 Gaucher disease. Mol Genet Metab. 2015;114:110-122.
LipsonAHRogersMBerryA.Collodion babies with Gaucher’s disease—a further case. Arch Dis Child. 1991;66:667.
9.
RozenbergRAraujoFTFoxDCet al. High frequency of mutation G377S in Brazilian type 3 Gaucher disease patients. Braz J Med Biol Res. 2006;39:1171-1179.
10.
SarriaAJGiraldoPPerez-CalvoJIPocoviM.Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher disease patients. Hum Mutat. 1999;14:88.
11.
ZhouYKraemerRRPekerDWakefieldDNde Idiaquez BakulaDA.Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1. Am J Hematol. 2013;88:922-923.
